N,N-Bis(5-aminosalicyl)-L-cystine is a potential colon-specific 5-aminosaiicylic acid prodrug with dual therapeutic effects in experimental colitis

Journal of Pharmaceutical Sciences

Volumn 98, Issue 1, 2009, Pages 159-168

  Kim, Heejung ^a   Huh, Jeoncsoon ^a   Jeon, Hyunchu ^a   Choi, Daekyu ^a   Han, Jungoh ^a   Kim, Young Mi ^a   Jung, Yunjin ^a  

^a Pusan National University   (South Korea)

Author keywords

5 aminosalicylic acid; Colon specific prodrug; Cystine; Glutathione and colitis

Indexed keywords

CYSTEINE; CYSTINE; DRUG METABOLITE; GLUTATHIONE; MESALAZINE; MYELOPEROXIDASE; N,N' BIS(5 AMINOSALICYL)CYSTINE; PRODRUG; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FECES LEVEL; DRUG URINE LEVEL; LARGE INTESTINE; MALE; NONHUMAN; RAT; TISSUE LEVEL; URINARY EXCRETION;

EID: 58149234000     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21404     Document Type: Article

References (27)

1. Yamada T, Grisham MB. 1991. Role of neutrophil-derived oxidants in the pathogenesis of intestinal inflammation. Klin Wochensehr 69:988-994.
2. McKenzie SJ, Baker MS, Buffinton GD, Doe WF. 1996. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 98:136-141.
3. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Verspa-get HW. 2003. Imbalaneed secondary mucosal anti-oxidant response in inflammatory bowel disease. J Pathol 201:17-27.
4. Siddiqui A, Ancha H, Tedesco D, Lightfoot S, Stewart CA, Harty RF. 2006. Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis. Dig Dis Sci 51:698-705.
5. Bulger EM, Helton WS. 1998. Nutrient antioxi-dants in gastrointestinal diseases. Gastroenterol Clin North Am 27:403-419.
6. Oz HS, Chen TS, McClain CJ, de Villiers WJ. 2005. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem 16:297-304.
7. Aw TY. 2005. Intestinal glutathione: Determinant of mucosal peroxide transport, metabolism, and oxidative susceptibility. Toxicol Appl Pharmacol 204:320-328.
8. Asanuma K, Iijima K, Sugata H, Ohara S, Shimo-segawa T, Yoshimura T. 2005. Diffusion of cytotoxic concentrations of nitric oxide generated luminally at the gastro-oesophageal junction of rats. Gut 54: 1072-1077.
9. Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, Droge W. 1998. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 42:485-492.
10. Crotty B, Jewell DP. 1992. Drug therapy of ulcera-tive colitis. Br J Clin Pharmacol 34:189-198.
11. Lofberg R. 2003. Review article: Medical treatment of mild to moderately active Crohn's disease. Aliment Pharmacol Ther 17:18-22.
12. Novis BH, Korzets Z, Chen P, Bernheim J. 1988. Nephrotic syndrome after treatment with 5-amino-salicylic acid. Br Med J (Clin Res Ed) 296:1442.
13. Sinha VR, Kumria R. 2001. Colonic drug delivery: Prodrug approach. Pharm Res 18:557-564.
14. Chourasia MK, Jain SK. 2003. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Sci 6:33-66.
15. Jung Y, Kim HH, Kim H, Kong H, Choi B, Yang Y, Kim Y. 2006. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Eur J Pharm Sci 28:26-33.
16. Jung YJ, Lee JS, Kim YM. 2001. Colon-specific prodrugs of 5-aminosalicylic acid: Synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J Pharm Sci 90:1767-1775.
17. Jung YJ, Lee JS, Kim YM. 2000. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J Pharm Sci 89:594-602.
18. Kim H, Kim D, Choi D, Jeon H, Han J, Jung Y, Kong H, Kim YM. 2008. Synthesis and properties of N,N'-bis(5-aminosalicyl)-L-cystine as a colon-specific deliverer of 5-aminosalicylic Acid and cystine. Drug Deliv 15:37-42.
19. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. 1989. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803.
20. Yano H, Hirayama F, Kamada M, Arima H, Uekama K. 2002. Colon-specific delivery of pre-dnisolone-appended alpha-cyclodextrin conjugate: Alleviation of systemic side effect after oral administration. J Control Release 79:103-112.
21. Son MW, Ko JI, Doh HM, Kim WB, Park TS, Shim MJ, Kim BK. 1998. Protective effect of taurine on TNBS-induced inflammatory bowel disease in rats. Arch Pharm Res 21:531-536.
22. Zhou SY, Fleisher D, Pao LH, Li C, Winward B, Zimmermann EM. 1999. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 27:479-485.
23. Scheline RR. 1973. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 25:451-523.
24. Ruh J, Schmidt E, Vogel F. 2003. Effect of N-acet-ylcysteine on microcirculation of mucosa in rat ileum in a model of intestinal inflammation. Dig Dis Sci 48:882-889.
25. Lee S, Moon SO, Kim W, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Lee SY, Park SK. 2006. Protective role of L-2-oxothiazolidine-4-ear-boxylic acid in cisplatin-induced renal injury. Nephrol Dial Transplant 21:2085-2095.
26. Mrnsy RJ. 1992. Drug absorption in the colon: a critical review. In: Friend DR, editor. Oral colon-specific drug delivery. Boca Raton, FL: CRC Press. 45-84.
27. Yan F, Polk DB. 1999. Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of Ikappa-Balpha in mouse intestinal epithelial cells. J Biol Chem 274:36631-36636.